ADIM
XYL icon

Alpha DNA Investment Management’s Xylem XYL Stock Holding History

Alpha DNA Investment Management’s Portfolio XYL Stock Details XYL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-9,886
Closed -$1.11M – 227
2023
Q2 		$1.11M Buy
+9,886
New +$1.05M 0.37% 50

Other funds holding XYL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Aristotle Capital Management
Aristotle Capital Management Los Angeles, California $47.8B AUM 13.38% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Amundi
Amundi Paris, France $367B AUM 31.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Alpha DNA Investment Management's XYL Position: Q3 2023 in Review

Alpha DNA Investment Management sold out of Xylem (XYL) in Q3 2023, closing a stake of 9,886 shares — an estimated $1.11M sold.

Alpha DNA Investment Management first reported a position in XYL in Q2 2023 and held it in 1 quarter. The position peaked at $1.11M in Q2 2023. 872 funds tracked by Wall St. Rank hold XYL as of Q3 2023.

  • Alpha DNA Investment Management reported no remaining Xylem position as of Q3 2023 after selling out during the quarter.
  • Alpha DNA Investment Management sold 9,886 Xylem shares in Q3 2023, an estimated $1.11M.
  • Alpha DNA Investment Management first reported a position in Xylem in Q2 2023 and held it in 1 quarter.
  • Alpha DNA Investment Management's Xylem position peaked at $1.11M in Q2 2023.
  • 872 funds tracked by Wall St. Rank held Xylem as of Q3 2023.

Based on Alpha DNA Investment Management's 13F filing for Q3 2023, filed 7 Nov 2023.